S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
S&P 500   4,452.90 (-0.06%)
DOW   35,040.70 (+0.70%)
QQQ   369.19 (-1.11%)
AAPL   144.78 (-1.46%)
MSFT   294.73 (-1.54%)
FB   349.76 (-0.91%)
GOOGL   2,823.16 (-0.74%)
TSLA   772.93 (-0.19%)
AMZN   3,343.90 (-2.38%)
NVDA   214.23 (-2.98%)
BABA   146.33 (+0.86%)
NIO   35.13 (-0.71%)
CGC   14.18 (+1.94%)
GE   105.97 (+2.09%)
MU   74.85 (+1.08%)
AMD   104.68 (-1.06%)
T   27.56 (+1.58%)
F   14.13 (+2.54%)
ACB   6.04 (+1.51%)
DIS   178.25 (+1.28%)
PFE   43.97 (+0.07%)
BA   227.59 (+2.80%)
BAC   43.11 (+2.30%)
CVE:DMA

DiaMedica Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume27,250 shs
Average Volume6,619 shs
Market CapitalizationC$36.38 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive DMA News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Headlines

DiaMedica Therapeutics Inc Registered Shs Buy
DiaMedica Therapeutics Inc Registered Shs Buy
February 19, 2021 |  markets.businessinsider.com
Insider Buys DiaMedica Therapeutics Stock
Insider Buys DiaMedica Therapeutics Stock
November 10, 2020 |  benzinga.com
DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
November 8, 2020 |  seekingalpha.com
DiaMedica Therapeutics EPS misses by $0.04
DiaMedica Therapeutics EPS misses by $0.04
November 6, 2020 |  seekingalpha.com
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
January 3, 2019 |  globenewswire.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

0.75 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











DiaMedica Therapeutics (CVE:DMA) Frequently Asked Questions

What stocks does MarketBeat like better than DiaMedica Therapeutics?

Wall Street analysts have given DiaMedica Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DiaMedica Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 58)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMA."

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics has a market capitalization of C$0.00 and generates C$503,657.00 in revenue each year.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

Where are DiaMedica Therapeutics' headquarters?

DiaMedica Therapeutics is headquartered at 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States. The company can be reached via phone at +1-763-4965454.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.